![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 11
Zeitschriftenartikel
Müller, V.; Banys-Paluchowski, M.; Friedl, T. W. P.; Fasching, P. A.; Schneeweiss, A.; Hartkopf, A.; Wallwiener, D.; Rack, B.; Meier-Stiegen, F.; Huober, J.; Rübner, M.; Hoffmann, O.; Müller, L.; Janni, W.; Wimberger, P.; Jäger, B.; Pantel, K.; Riethdorf, S.; Harbeck, N. und Fehm, T.
(2021):
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.
In: Esmo Open, Bd. 6, Nr. 6
Jäger, B. A. S.; Neugebauer, J.; Andergassen, U.; Melcher, C.; Schochter, F.; Mouarrawy, D.; Ziemendorff, G.; Clemens, M.; Abel, E. v.; Heinrich, G.; Schüller, K.; Schneeweiss, A.; Fasching, P.; Beckmann, M. W.; Scholz, Ch.; Friedl, T. W. P.; Friese, K.; Pantel, K.; Fehm, T.; Janni, W. und Rack, B.
(2017):
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
In: PLOS One 12(6), e0173593 [PDF, 1MB]
In: PLOS One 12(6), e0173593 [PDF, 1MB]
Janni, W.; Rack, B.; Häberle, L.; Friedl, T. W. P.; Tesch, H.; Lorenz, R.; Jäger, B.; Fehm, T.; Müller, V.; Schneeweiß, A.; Lichtenegger, W.; Blohmer, J.; Beckmann, M. W.; Scholz, C.; Pantel, K.; Trapp, E. und Fasching, P. A.
(2017):
Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent prognosis.
In: Cancer Research, Bd. 77
Polasik, A.; Schramm, A.; Friedl, T. W. P.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Janni, W. und Fehm, T.
(2017):
DETECT III and IV - Individualized CTC-based therapy of metastatic breast cancer.
In: Cancer Research, Bd. 77
Polasik, A.; Schramm, A.; Friedl, T. W. P.; Rack, B.; Trapp, E.; Tzschaschel, M.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Janni, W. und Fehm, T.
(2017):
The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo-or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer.
In: Cancer Research, Bd. 77
Tzschaschel, M. L. J.; Rack, B.; Andergassen, U.; Friedl, T. W. P.; Schneeweiss, A.; Müller, V.; Tanja, F.; Pantel, K.; Gade, J.; Lorenz, R.; Rezai, M.; Tesch, H.; Soeling, U.; Polasik, A.; Alunni-Fabbroni, M.; Trapp, E. K.; Mahner, S.; Schindlbeck, C.; Lichtenegger, W.; Beckmann, M. W.; Fasching, P. A. und Janni, W.
(2017):
Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients Results from the adjuvant SUCCESS A trial.
In: Cancer Research, Bd. 77
Janni, W.; Schramm, A.; Friedl, T. W. P.; Schochter, F.; Huober, J.; Rack, B.; Alunni-Fabbroni, M.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Krawczyk, N.; Pantel, K. und Fehm, T.
(2016):
Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer.
In: Cancer Research, Bd. 76
Schramm, A.; Friedl, T.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Kümmel, S.; Gebauer, G.; Müller, L.; Janni, W. und Fehm, T.
(2016):
The DETECT Study Concept - Metastatic breast cancer and circulating tumor cells.
In: Oncology Research and Treatment, Bd. 39: S. 46-47
Janni, W.; Schramm, A.; Friedl, T. W. P.; Schochter, E.; Huober, J.; Rack, B.; Alunni-Fabbroni, M.; Fasching, P. A.; Taran, F.-A.; Hortkopf, A.; Schneeweiss, A.; Mueller, V.; Aktas, B.; Krawczyk, N.; Pantel, K. und Fehm, T.
(2016):
Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer.
In: Oncology Research and Treatment, Bd. 39: S. 47
Janni, W.; Rack, B.; Fasching, P.; Haeberle, L.; Friedl, T.; Tesch, H.; Lorenz, R.; Neugebauer, J.; Koch, J.; Jaeger, B.; Fehm, T.; Mueller, V.; Schneeweiß, A.; Lichtenegger, W.; Beckmann, M.; Scholz, C.; Pantel, K. und Trapp, E.
(2016):
Persistence of circulating tumor cells in high risk early breast cancer patients during follow-up care suggests poor prognosis - Results from the adjuvant SUCCESS A trial.
In: Cancer Research, Bd. 76
Janning, M.; Müller, V; Vettorazzi, E.; Cubas-Cordova, M.; Gensch, V; Ben Batalla, I; Eulenburg, C. zu; Schem, C.; Fasching, P. A.; Schnappauf, B.; Karn, T.; Fehm, T.; Just, M.; Kühn, T.; Holms, F.; Overkamp, F.; Krabisch, P.; Rack, B.; Denkert, C.; Untch, M.; Tesch, H.; Rezai, M.; Kittel, K.; Pantel, K.; Bokemeyer, C.; Loibl, S.; Minckwitz, G. von und Loges, S.
(2016):
Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.
In: Oncology Research and Treatment, Bd. 39: S. 185